Aymanshafei (Talk | contribs) |
Aymanshafei (Talk | contribs) |
||
Line 10: | Line 10: | ||
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"> | <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"> | ||
<meta name="viewport" content="width=device-width, initial-scale=1.0"> | <meta name="viewport" content="width=device-width, initial-scale=1.0"> | ||
+ | <style> | ||
+ | *{ | ||
+ | margin: 0; | ||
+ | padding: 0; | ||
+ | -webkit-box-sizing: border-box; | ||
+ | -moz-box-sizing: border-box; | ||
+ | box-sizing: border-box; | ||
+ | } | ||
+ | .theme-mi-slider .nivoSlider{ | ||
+ | position:relative; | ||
+ | } | ||
+ | |||
+ | .theme-mi-slider .nivoSlider a { | ||
+ | border:0; | ||
+ | display:block; | ||
+ | } | ||
+ | .nivo-controlNav{ | ||
+ | display: flex; | ||
+ | justify-content: center; | ||
+ | } | ||
+ | |||
+ | .theme-mi-slider .nivo-control{ | ||
+ | display: block; | ||
+ | width: 18px; | ||
+ | height: 18px; | ||
+ | border-radius: 50%; | ||
+ | background: #545454; | ||
+ | margin: 3px; | ||
+ | text-indent: -9999px | ||
+ | } | ||
+ | |||
+ | .theme-mi-slider .nivo-control:hover{ | ||
+ | background: #1B1B1B; | ||
+ | } | ||
+ | |||
+ | .theme-mi-slider .active{ | ||
+ | background: #1B1B1B; | ||
+ | } | ||
+ | .nivo-directionNav a{ | ||
+ | display: block; | ||
+ | width: 30px; | ||
+ | height: 30px; | ||
+ | } | ||
+ | |||
+ | .nivo-directionNav .nivo-prevNav{ | ||
+ | background-image: url(../img/icons/circle-left.png); | ||
+ | background-size: cover; | ||
+ | text-indent: -9999px; | ||
+ | left: 6px; | ||
+ | } | ||
+ | |||
+ | .nivo-directionNav .nivo-nextNav{ | ||
+ | background-image: url(../img/icons/circle-right.png); | ||
+ | background-size: cover; | ||
+ | text-indent: -9999px; | ||
+ | right: 6px; | ||
+ | } | ||
+ | .nivo-html-caption{ | ||
+ | position: absolute; | ||
+ | } | ||
+ | .nivoSlider { | ||
+ | position:relative; | ||
+ | width:100%; | ||
+ | height:auto; | ||
+ | overflow: hidden; | ||
+ | } | ||
+ | .nivoSlider img { | ||
+ | position:absolute; | ||
+ | top:0px; | ||
+ | left:0px; | ||
+ | max-width: none; | ||
+ | } | ||
+ | .nivo-main-image { | ||
+ | display: block !important; | ||
+ | position: relative !important; | ||
+ | width: 100% !important; | ||
+ | } | ||
+ | |||
+ | /* If an image is wrapped in a link */ | ||
+ | .nivoSlider a.nivo-imageLink { | ||
+ | position:absolute; | ||
+ | top:0px; | ||
+ | left:0px; | ||
+ | width:100%; | ||
+ | height:100%; | ||
+ | border:0; | ||
+ | padding:0; | ||
+ | margin:0; | ||
+ | z-index:6; | ||
+ | display:none; | ||
+ | background:white; | ||
+ | filter:alpha(opacity=0); | ||
+ | opacity:0; | ||
+ | } | ||
+ | /* The slices and boxes in the Slider */ | ||
+ | .nivo-slice { | ||
+ | display:block; | ||
+ | position:absolute; | ||
+ | z-index:5; | ||
+ | height:100%; | ||
+ | top:0; | ||
+ | } | ||
+ | .nivo-box { | ||
+ | display:block; | ||
+ | position:absolute; | ||
+ | z-index:5; | ||
+ | overflow:hidden; | ||
+ | } | ||
+ | .nivo-box img { display:block; } | ||
+ | |||
+ | /* Caption styles */ | ||
+ | .nivo-caption { | ||
+ | position:absolute; | ||
+ | top: 40%; | ||
+ | left:0px; | ||
+ | bottom:0px; | ||
+ | font-family: sans-serif; | ||
+ | text-align: center; | ||
+ | color:#fff; | ||
+ | width:100%; | ||
+ | z-index:8; | ||
+ | padding: 5px 10px; | ||
+ | overflow: hidden; | ||
+ | display: none; | ||
+ | } | ||
+ | .nivo-caption p { | ||
+ | padding:5px; | ||
+ | margin:0; | ||
+ | } | ||
+ | .nivo-caption a { | ||
+ | display:inline !important; | ||
+ | } | ||
+ | .nivo-html-caption { | ||
+ | display:none; | ||
+ | } | ||
+ | /* Direction nav styles (e.g. Next & Prev) */ | ||
+ | .nivo-directionNav a { | ||
+ | position:absolute; | ||
+ | top:45%; | ||
+ | z-index:9; | ||
+ | cursor:pointer; | ||
+ | } | ||
+ | .nivo-prevNav { | ||
+ | left:0px; | ||
+ | } | ||
+ | .nivo-nextNav { | ||
+ | right:0px; | ||
+ | } | ||
+ | /* Control nav styles (e.g. 1,2,3...) */ | ||
+ | .nivo-controlNav { | ||
+ | text-align:center; | ||
+ | padding: 15px 0; | ||
+ | } | ||
+ | .nivo-controlNav a { | ||
+ | cursor:pointer; | ||
+ | } | ||
+ | .nivo-controlNav a.active { | ||
+ | font-weight:bold; | ||
+ | } | ||
+ | </style> | ||
</head> | </head> | ||
<body> | <body> | ||
Line 162: | Line 322: | ||
</div> <!-- /.owl-carousel --> | </div> <!-- /.owl-carousel --> | ||
</section> | </section> | ||
+ | <div class="slider-wrapper theme-mi-slider"> | ||
+ | <div id="slider" class="nivoSlider" style="max-height:400px"> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/6/60/9-AFCM-Egypt-sponsers-Benchling.png" alt="" title="#htmlcaption1" /> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/6/60/9-AFCM-Egypt-sponsers-Benchling.png" alt="" title="#htmlcaption2" /> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/6/60/9-AFCM-Egypt-sponsers-Benchling.png" alt="" title="#htmlcaption3" /> | ||
+ | </div> | ||
+ | <div id="htmlcaption1" class="nivo-html-caption"> | ||
+ | <h1>test new slider</h1> | ||
+ | <p>test new slider</p> | ||
+ | </div> | ||
+ | <div id="htmlcaption2" class="nivo-html-caption"> | ||
+ | <h1>test new slider</h1> | ||
+ | </div> | ||
+ | <div id="htmlcaption3" class="nivo-html-caption"> | ||
+ | <h1>test new slider</h1> | ||
+ | </div> | ||
+ | </div> | ||
<script src="https://2017.igem.org/Template:AFCM-Egypt/owl.carouseljs/javascript?action=raw&ctype=text/javascript"></script> | <script src="https://2017.igem.org/Template:AFCM-Egypt/owl.carouseljs/javascript?action=raw&ctype=text/javascript"></script> | ||
<script> | <script> |
Revision as of 23:52, 16 October 2017
Abstract
Knock-in of Circular RNA gene in Hepatocellular Carcinoma cells via CRISPR/Cas9
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers
in males and next to breast cancer among females in Egypt - based upon results of National Cancer Registry Program of Egypt-.
"Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique
that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma.
This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials.
This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers in males and next to breast cancer among females in Egypt - based upon results of National Cancer Registry Program of Egypt-. "Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma. This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials. This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.